Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

1. Winer, E.P.
2. Lipatov, O.
3. Im, S.-A.
4. Goncalves, A.
5. Muñoz-Couselo, E.
6. Lee, K.S.
7. Schmid, P.
8. Tamura, K.
9. Testa, L.
10. Witzel, I.
11. Ohtani, S.
12. Turner, N.
13. Zambelli, S.
14. Harbeck, N.
15. Andre, F.
16. Dent, R.
17. Zhou, X.
18. Karantza, V.
19. Mejia, J.
20. Cortes, J.